Shares of Bristol Myers Squibb Co. BMY advanced 1.17% to $48.46 Monday, on what proved to be an all-around positive trading ...

Leading health technology company MentalHealth.com is pleased to announce its acquisition of online mental health resource ...

Adding pembrolizumab (Keytruda), before and after surgery, to standard adjuvant therapy for locally advanced head and neck ...

The CR rate was consistent across subgroups including men and women, patients with and without papillary disease, and ...

The guidance revisions include the estimated impact of current tariffs on U.S. products shipped to China, but not Trump’s ...

Bristol Myers Squibb & Co (NYSE:BMY) reported first-quarter 2025 revenues of $11.20 billion, beating the consensus of $10.70 ...

The stock's rise snapped a four-day losing streak.

Bristol Myers Squibb reported better-than-expected earnings for the first quarter and boosted its outlook while noting the ...

Compared with placebo, xanomeline/trospium as an add-on to atypical antipsychotics has not reached the threshold for a ...

Bristol-Myers Squibb is undervalued with a 5%+ dividend yield, robust pipeline, and recession-resistant business. Click here ...

Bristol-Myers Squibb raised its 2025 EPS outlook after a Q1 beat, with shares trading far below historical P/E levels. Find ...

Bill Strazzullo, Bell Curve Trading chief market strategist, said in a latest program on CNBC that the market isn’t done ...